CRITICAL DOCUMENTATION REQUIREMENTS FOR VALIDATION. Paul L. Pluta, PhD

Size: px
Start display at page:

Download "CRITICAL DOCUMENTATION REQUIREMENTS FOR VALIDATION. Paul L. Pluta, PhD"

Transcription

1 CRITICAL DOCUMENTATION REQUIREMENTS FOR VALIDATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy Chicago, IL, USA 1

2 PRESENTATION OUTLINE Process Validation General Validation Documents Overview Validation Policy Documents Stage 1 Process Design Documents Stage 2 Process Qualification Documents Validation Requests and Plans Validation Protocols Validation Results and Reports Stage 3 Continued Process Verification Documents Associated Documents Document Outlines / Templates Document Problems Implementation of PV Guidance Recommendations Interactions throughout discussion PARTICIPATION INVITED 2

3 OBJECTIVES 1. Comprehensive and consistent approach to documentation 2. Lifecycle approach principles and key concepts 3. Document details Outlines Examples Problems 4. Implementation 3

4 IMPORTANCE OF VALIDATION DOCUMENTS Validation documents always requested in regulatory audits Documentation is retained forever Documents reviewed long after people are gone Documents must stand alone Early documents (Request, Plan, Protocol) reviewed when project is in-progress or not completed Regulatory auditors often focus on documentation validation documents often requested ahead of audit Above sometimes difficult for technical people 4

5 IMPORTANCE OF VALIDATION DOCUMENTS NEW PROCESS VALIDATION GUIDANCE FDA Process Validation Guidance has greatly expanded the scope of validation Lifecycle approach documents from development through commercialization Traditional validation documents (protocol and results) less important Validation organizations should lead sites in transition to lifecycle approach Multiple groups at site must now contribute to process validation lifecycle approach Lifecycle approach being applied to all validation and qualification (equipment, facilities, cleaning, etc.) 5

6 TERMINOLOGY: PROCESS VALIDATION Process Validation Process Qualification Qualification Equipment #1 Equipment #2 Equipment #3 UO #1 UO #2 UO #3 Qualification HVAC Utilities Facilities Computers Analytical methods validation Cleaning process validation Packaging process validation Process is validated 6

7 FDA PROCESS VALIDATION GUIDANCE (2011) Definition: Collection and evaluation of data, from the process design stage throughout commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. Process validation involves a series of activities over the lifecycle of the product and process. Three stages of activities: Stage 1 Process Design Development and scale-up activities Stage 2 Process Qualification Reproducible manufacturing Stage 3 Continued Process Verification Routine manufacturing STAGE 1 AND STAGE 3 EMPHASIS NEW PARADIGM 7

8 FDA PROCESS VALIDATION GUIDANCE DOCUMENTATION FOCUS Before commercial distribution to consumers, a manufacturer should have gained a high degree of assurance in the performance of the manufacturing process consistently produce Manufacturers should: Understand the sources of variation Detect the presence and degree of variation Understand the impact of variation on the process and product attributes Control the variation in a manner commensurate with risk to process and product. to justify commercial distribution of the product. use ongoing programs to collect and analyze product and process data state if control of the process. 8

9 FDA PROCESS VALIDATION GUIDANCE DOCUMENTATION FOCUS Good project management and good archiving to capture scientific knowledge. Enhance accessibility of information later in lifecycle. Integrated team approach: Process engineering, industrial pharmacy, analytical chemistry, microbiology, statistics, manufacturing, and quality assurance. Scientific studies throughout the product lifecycle planned, documented, and approved. Greater control over higher-risk attributes. Reevaluate risks throughout product/process lifecycle. Homogeneity with batch and consistency between batches are goals of process validation. 9

10 STAGE 1, PROCESS DESIGN (PROCESS UNDERSTANDING) 1. Building and capturing process knowledge and understanding. 2. Establishing a strategy for process control. Define commercial-scale process Define unit operations and process parameters Identify and understand sources of variability Identify critical process parameters Studies to understand effects of scale Establish mechanisms to control variability Process Analytical Technology Designed experiments Lab scale and pilot scale experiments 10

11 PROCESS DESIGN (PROCESS UNDERSTANDING) Objective API and excipient pharmaceutics Quality attributes Risk analysis Process parameters Design of experiments Design space Normal operating range In-process controls Product development key inputs to design stage Variability by different component lots, production operators, environmental conditions, and measurement systems Use risk analysis tools to screen variables Establish a strategy for process control 11

12 QUALITY BY DESIGN (QbD) 1. Quality target product profile (QTTP) 2. Critical quality attributes (CQA), critical material attributes (CMA) 3. Critical process parameters (CPP) 4. Design space 5. Scale-up and technology transfer 6. Identify input variables 7. Input variable control strategy 8. Continuous improvement Other considerations: PAT, Risk analysis 12

13 STAGE 2, PROCESS QUALIFICATION (VALIDATION PERFORMANCE) 1. Design of a facility and qualification of utilities and equipment 2. Process performance qualification 3. PPQ protocol 4. PPQ protocol execution and report Confirmation at commercial scale of process design information Qualification of equipment, utilities, facilities Performance qualification Conclusion that process consistently produces quality product. Conformance batches All support systems, documents, training, personnel, etc. in place Target / nominal operating parameters within design space Additional testing Decision to release process for routine commercial manufacturing 13

14 STAGE 2, PROCESS QUALIFICATION Conformance Lots Procedures Validation plans Protocols Sampling Testing Results Plan to maintain validation ALL EQUIPMENT, ANALYTICAL, AND SUPPORTING SYSTEMS MUST BE QUALIFIED. 14

15 PERFORMANCE QUALIFICATION APPROACH Higher level of sampling, testing, and scrutiny of process performance. Protocol should address: Operating parameters, processing limits, and raw material inputs Data to be collected and how evaluated Test to be performed and acceptance criteria Sampling plan sampling points, number of samples, frequency Statistical methods used Statistical confidence levels Provisions to address deviations and non-conformances Facility, utility, and equipment qualification Personnel training Status of analytical method validation Review and approval by appropriate departments and quality unit DETAILS FROM PV GUIDANCE 15

16 PERFORMANCE QUALIFICATION APPROACH The PPQ lots should be manufacturer under normal conditions by personnel expected to routinely perform each step of each unit operation in the process. Normal operating conditions should cover the utility systems (air handling and water purification), material, personnel environment, and manufacturing procedures. PQ report: Discuss all aspects of protocol Summarize and analyze data as specified in protocol Evaluate unexpected observations and additional data Summarize and discuss non-conformances Describe corrective actions or changes Clear conclusions Approval by appropriate departments and quality unit DETAILS FROM PV GUIDANCE 16

17 STAGE 3, CONTINUED PROCESS VERIFICATION (VALIDATION MONITORING AND MAINTENANCE) Activities to assure process remains in validated state Annual Product Review Trend and assess data Study OOS and OOT (Out of Trend) data Timely monitoring of critical operating and performance parameters. Monitor product characteristics, materials, facilities, equipment, and SOP changes Establish process history based on ongoing process performance Improve process Improve control to detect and reduce variability Change control; evaluate impact of change and test as necessary 17

18 CONTINUED PROCESS VERIFICATION Monitoring Statistical process control Trend analysis Change control Continuous improvement Revalidation Management review STATISTICIAN RECOMMENDED BY FDA 18

19 CONTINUED PROCESS VERIFICATION ITEMS TO BE REVIEWED Product and process data Relevant process trends Quality of incoming materials or components In-process material Finished products Defect complaints OOS findings Deviations Yield variations Batch records Incoming raw material records Adverse event reports Production operator and quality staff feedback Above should help identify possible product / process improvements DETAILS FROM PV GUIDANCE 19

20 SUMMARY OF GUIDANCE RECOMMENDATIONS Stage 1: Product Design QTPP, Development information, Identification of CQA, CMA, and CPP Identification of sources of variation and control plan Experimental studies Technology transfer / scale up Stage 2: Process Qualification Protocol requirements Statistical sampling and acceptance criteria Equipment qualification and analytical method validation Stage 3: Continued Process Verification Post PQ plan APR, batch data, yields, deviations, OOS, non-conformances, etc. Incoming material data Change control Statistical analysis of data / control charting Product complaints 20

21 PROCESS VALIDATION HISTORY 1978 CGMP includes Validation 1987 Development -- VALIDATION -- Control Lifecycle approach Continuum of understanding validation maintenance UNDERSTANDING -- VALIDATION -- MAINTENANCE 21

22 VALIDATION PHILOSOPHY Validation is confirmation. Acceptable (passing) results are expected. Validation is not R&D Final stage of development process Optimization Fine-tuning Debugging 22

23 VALIDATION DOCUMENTS Written for the reader US vs. Europe Objective: Understanding Clarity much more important than brevity Stand-alone document Potential for review in 10+ years Author / Management not available for explanation Spelling and grammar correct Need good writers Simple sentences Simple words 23

24 PROCESS VALIDATION DOCUMENTS Validation policy Reference lifecycle approach Corporate templates Validation Master Plan (VMP) Reference lifecycle approach Stage 1 documents Process Design Stage 2 documents Process Qualification Validation Request / Plan -- Reference Guidance Validation Protocol(s) Reference Guidance Engineering Studies Others Validation Results / Report Reference Guidance Stage 3 documents Continued Process Verification PQ requirements Routine monitoring Reference lifecycle approach Associated validation and qualification -- Reference lifecycle approach Other associated documents 24

25 VALIDATION POLICY Corporate or company policies High level overview documents Apply to all global manufacturing sites State agreement with local regulatory requirements State agreement with customer regulatory documents Specific corporate requirements Describe general validation approach 25

26 VALIDATION POLICY Describe general validation approach Design and development. Science and technical basis Validation performance Maintain validated state through monitoring, change control, and management review Risk analysis emphasis on highest risk Sampling, testing, acceptance criteria Variation identification and control Continuing improvements GENERAL POLICY WITH KEY POINTS 26

27 VALIDATION MASTER PLAN (VMP) PROGRAM DESCRIPTION AT SITE Comprehensive lifecycle approach based on risk Consistent with general policy MULTI-CHAPTER DOCUMENT Chapter for each major area (may have individual VMP per area) Process Equipment Facilities Analytical Computer Others UPDATED AS NEEDED (Annual, quarterly, monthly) VMP must be current for audits IMPROVEMENT PROJECTS COMMITMENTS AND TIMELINES 27

28 VALIDATION MASTER PLAN (VMP) SITE PROGRAM DESCRIPTION Design and development. Science and technical basis Validation performance Maintain validated state through monitoring, change control, and management review Risk analysis emphasis on high risk activities Variation identification and control Continuing improvements 28

29 VALIDATION MASTER PLAN (VMP) CHAPTER CONTENT Content for processes, cleaning, analytical, etc. Strategy and approach Procedures Supporting information (reference) Ex: Product validation families, Cleaning matrix Validation references Ex: Products, equipment, utilities, etc. document ID Validation commitments and timelines Improvement projects and timelines 29

30 VMP CHAPTER EXAMPLE CLEANING VALIDATION Strategy and approach Comprehensive lifecycle approach, Science and technical basis, Risk analysis, Variation identification and control (consistent with site and corporate docs) Procedures List of approved procedures Supporting information with reference documentation Product cleaning matrix Equivalent equipment Equipment surface area calculations Residue calculations Technical reports Templates Validation references List of all completed cleaning validation Validation commitments and timelines Planned validations Improvement projects and timelines Planned projects 30

31 STAGE 1 DOCUMENTS -- PROCESS DESIGN Technical areas must be aware that their documents are critical to validation throughout the product lifecycle. Direct support of Stage 2 PQ their work is basis of validation R&D technical reports consistent with raw data Rapidly retrieved (within 30 minutes) Accessed throughout product lifecycle Personal support of regulatory audits Stand-alone documents Applies to processes, cleaning, analytical, equipment, facilities, utilities, control systems, others. R&D / TECHNICAL AREAS NOT ACCUSTOMED TO THESE REQUIREMENTS AND EXPECTATIONS 31

32 STAGE 1 DOCUMENTS POTENTIAL PROBLEMS Reports not available Reports not retrievable Reports incomplete Reports poorly written Reports not approved Personnel not available Original data not available Substandard documentation practices original data No signature / date Data transpositions Data transfer problems Data transfer not verified Inconsistent data Multiple sources of same data inconsistent 32

33 VALIDATION STAGE 2 DOCUMENTS OPTIONS Outlines Templates Model documents RECOMMENDATION 1. Develop outlines for authors get agreements from functional organizations and approval committee 2. Write or collect good documents 3. Documents available to writers 4. Replace (upgrade) as appropriate 33

34 STAGE 2 DOCUMENTS PROCESS QUALIFICATION VALIDATION REQUEST AND VALIDATION PLAN INITIATION OF VALIDATION Request: Statement of recommended validation What? Why needed? Why acceptable? Impact of validation risk analysis Approach to accomplish Validation Plan Approvals Plan: Details of work to accomplish validation Description of strategy and approach References from Stage 1 work supporting validation Approvals MAY BE SINGLE DOCUMENT OR TWO SEPARATE DOCUMENTS 34

35 VALIDATION REQUEST OUTLINE Objective of validation Why needed? Impact of validation Risk analysis Why acceptable? Compliance to internal requirements, policies, engineering standards, etc. Regulatory impact (Prior approval, CBE, CBE30, etc.) Other systems or product impacted Procedure changes or other document changes Notifications to affected groups (internal, external, labs) Validation plan -- Approach to accomplish validation Above applicable to equipment and other qualification HAVE MODEL DOCUMENTS AVAILABLE 35

36 VALIDATION REQUEST -- PROBLEMS Poorly written Inadequate information Prematurely written Written to meet business goals Written to demonstrate future intent Amendments necessary -- changes usually required Validation requests should be submitted for approval only after objective and scope of validation is determined and work details (risk/testing/sampling) determined. Amendments are a planning failure regardless of justification. HAVE MODEL DOCUMENTS AVAILABLE 36

37 VALIDATION REQUEST TERMINOLOGY EXAMPLES Validation request: Process validation of Product A System: New product validation Change impact: High impact. New product validation Reason: New product to be manufactured at site Acceptability: Compliant with policies Regulatory approval Other systems impacted (e.g., cleaning) Procedures approved Notifications (Labs) Justification: See Validation Plan Approvals SIMPLE AND CLEAR 37

38 VALIDATION REQUEST TERMINOLOGY EXAMPLES Validation request: Qualification of 150 cu. ft. blender System: New equipment qualification Change impact: High impact. New equipment and new size at site Reason: New equipment to increase manufacturing efficiency and throughput Acceptability: Compliant with policy Regulatory approval Other systems impacted (e.g., cleaning) Procedures approved Notifications (Labs) Justification: See Validation Plan Approvals SIMPLE AND CLEAR 38

39 VALIDATION REQUEST TERMINOLOGY EXAMPLES Validation request: Change air supply and return ductwork to coincide with Line 1 floor space changes System: HVAC system #3 Change impact: Medium impact. Change to direct product contact support utility Reason: Room configuration change to increase manufacturing efficiency Acceptability: Compliant with policy Regulatory approval not needed Other systems impacted Procedures approved, drawings modified, etc. Notifications Justification: See Validation Plan Approvals SIMPLE AND CLEAR 39

40 Introduction VALIDATION PLAN OUTLINE Technical information Validation strategy and testing -- rationale Validation documentation List of required protocols, reports, procedures, etc. Administrative benefit References List of reports and scientific references (including Stage 1 reports) HAVE MODEL DOCUMENTS AVAILABLE 40

41 INTRODUCTION VALIDATION PLAN Overview describing validation / product / process / equipment / etc. (consistent with request) Requirements to complete validation Conformance to regulations and internal policy Impact of change to maintain the validated state Impact on regulatory submission Impact of change on procedures, drawings, other documents Notifications to other areas internal and external (e.g., environmental agency, internal test labs) impacted by validation 41

42 TECHNICAL INFORMATION VALIDATION PLAN Basic product / process / equipment description Formula Process Specifications Include non-technical description information Technical aspects of validation / qualification Reference to technical reports from Design Stage Total validation approach Experimental studies Past data (retrospective data) Validation protocols Other work New procedures Number of lots related to impact of change and risk WRITTEN FOR THE READER 42

43 VALIDATION PLAN VALIDATION STRATEGY AND TESTING Prospective validation only Types of testing -- general Regulatory specifications Internal controls Process tests Tests and rationale general Address changes based on risk analysis Sampling and rationale general Exceed routine QA testing based on impact and risk analysis Data treatment general Statistical data treatment and confidence limits Acceptance criteria general DETAILS OF ABOVE PROVIDED IN PROTOCOLS 43

44 VALIDATION PLAN VALIDATION DOCUMENTATION Doc # Title Date closed 01 Validation request 02 XXX Dryer Engineering Study 03 XXX Dryer Qualification 04 XXX Process Scale-up Engineering Study 05 XXX Process Validation 06 Update Validation Master Plan Product and Equipment sections 07 XXX Project Summary Report 44

45 VALIDATION PLAN REFERENCES R&D Reports Development and analytical reports Published literature Scientific and technical support to validation plan Report copies should be stored in validation area or readily accessible (within 30 minutes) 45

46 PRODUCT / PROCESS DESIGN INFORMATION Technical reports from R&D Pharmaceutics reports Formulation and process development reports (CQA, CMA, CPP) Technology transfer / Scale-up reports Identification of sources of variation Variation control plans Analytical methods Other technical reports REPORTS SHOULD BE REVIEWED FOR CONSISTENCY BETWEEN GROUPS REPORTS SHOULD BE REFERENCED IN VALIDATION PLAN 46

47 TECHNICAL REPORTS Readily available Consistent across large technical groups Approved by management Linked to original data Observe / store original data Original documentation practices? VALIDATION MUST REVIEW ORIGINAL DATA Rapidly retrievable Consistent with technical report Documentation practices 47

48 VALIDATION PROTOCOLS Execution of the Validation Plan Testing details Sampling details Data sheets Data treatment Acceptance criteria Minimal text repetition from Validation Plan PROTOCOL EASILY WRITTEN IF VALIDATION PLAN IS THOROUGH 48

49 VALIDATION PROTOCOL Objective of validation specific protocol Validation description specific Validation approach Testing and rationale -- specific Sampling and rationale -- specific Data sheets (summary) Data treatment -- specific Acceptance criteria specific All testing must have acceptance criteria No FYI testing in validation VALIDATION IS CONFIRMATION 49

50 VALIDATION PROTOCOL TESTING AND SAMPLING Based on product specifications and testing Exceed routine QA testing based on impact and risk Consider the following: Product for seizures Product for hypertension New product Change in compressing machine Increase compressing machine speed Change in granulation method Change in batch size Risk analysis in above 50

51 VALIDATION PROTOCOL FDA Powder Blends and Finished Dosage Units Stratified Sampling and Assessment Blend sampling. n = 10, Individuals, RSD Tablets. 20 samples, n = 3-7 per location, mean, range, RSD. Application is possible approach for high risk products Supportive of USP Uniformity of Dosage Units on composite / stratified samples Product types: Potency and weight testing 51

52 VALIDATION SAMPLING What is routine QA sampling? Impact of change High impact Medium impact Low impact No impact Risk analysis Related to numerical RPN analysis High risk Medium risk Low risk RISK LEVEL MUST BE ACKNOWLEDGED 52

53 ENGINEERING STUDY Conducted in advance of validation No acceptance criteria Trial run Examples: Manufacturing process without bulk drug (low dose API) Process runs with placebo Categories of Engineering Studies Conduct Engineering Study concurrently with validation? - - Not recommended 53

54 SAMPLING PAGES Designed sheet with space for expected data Data treatment specified Signature and data of person supplying data Highly recommended for Operators or persons not familiar with sampling Data pages consistent with sampling pages Prevents missing data in complex protocols Record sampling and / or testing 54

55 SAMPLING / DATA PAGE EXAMPLE UNIT OPERATION: Tablet compressing, lot # TEST: Content Uniformity (SOP # XX-XXX) SAMPLE: 10 Tables each from beginning, middle, and end of batch Sample #1 by Date Sample #2 by Date Sample #3 by Date TEST RESULTS (Circle P -- Pass or F -- Fail) Sample #1 Sample #2 Sample #3 P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F P / F RECORDED BY: VERIFIED BY: 55

56 PROCESS VALIDATION PROTOCOL (PPQ) FDA GUIDLINE RECOMMENDATIONS Higher level of sampling, testing, and scrutiny of process performance. Protocol should address: Operating parameters, processing limits, and raw material inputs Data to be collected and how evaluated Test to be performed and acceptance criteria Sampling plan sampling points, number of samples, frequency Statistical methods used Statistical confidence levels Provisions to address deviations and non-conformances Facility, utility, and equipment qualification Status of analytical method validation Review and approval by appropriate departments and quality unit 56

57 HEALTH CANADA PROTOCOL REQUIREMENTS Minimum information Objective, scope of coverage of the validation study Validation team membership, qualifications, and responsibilities Type of validation prospective, concurrent, retrospective, re-validation Number and selection of batches List of all equipment used. Normal and worst-case operating parameters Outcome of IQ and OQ for critical equipment Requirements for calibration of all measuring devices Critical process parameters and tolerances Description of processing steps. Copy of master documents Sampling points, stages of sampling, methods of sampling, sampling plans Statistical tools for data analysis Training requirements for processing operators Validated test methods Specification for raw and packaging materials and test methods Forms and charts for documenting results Format for presentation of results, documenting conclusions, and approval of study results 57

58 VALIDATION PROTOCOL OUTLINE Introduction Unit operations Testing with justification Sampling with justification Sampling and data pages Data treatment Acceptance criteria with justification HAVE MODEL DOCUMENTS AVAILABLE 58

59 VALIDATION PROTOCOL -- PROBLEMS No plan No basic explanation of validation No statement of strategy and approach No test rationale No sampling rationale Missing samples missing data How to treat data No discussion of results No acceptance criteria rationale No validation statement Poorly written WRITTEN FOR THE READER 59

60 VALIDATION PROTOCOL -- PROBLEMS How many lots should be tested? Consider impact of change. Consider product. Consider process. Consider risk. ABOVE ADDRESSED IN VALIDATION PLAN 60

61 VALIDATION RESULTS Compilation of testing required in protocol Deviations or adverse events Discussion Conclusion WRITE GOOD PLAN PROTOCOL CONSISTENT WITH PLAN RESULTS CONSISTENT WITH PROTOCOL WRITE DISCUSSION FIRST MOST IMPORTANT SECTION 61

62 VALIDATION RESULTS OUTLINE Introduction Data sheets compiled Data treatment Results Deviations, Non-conformances, etc. Discussion Results pass is not sufficient. Validation statement: Results indicate that is validated. Post-validation monitoring plan WRITE DISCUSSION SECTION FIRST MOST IMPORTANT SECTION HAVE MODEL DOCUMENTS AVAILABLE 62

63 VALIDATION RESULTS PROBLEMS Missing data Documentation practices on raw data Raw data and results inconsistent Inadequate or no discussion of results Inadequate or no discussion of amendments or deviations No conclusion statement Poor grammar and composition 63

64 VALIDATION RESULTS / REPORT -- PROBLEMS Protocol requires BME samples for potency. Acceptance criteria: % B = 95% M = 100% E = 105% All results pass Conclusion? POST PQ MONITORING? 64

65 VALIDATION RESULTS / REPORTS -- PROBLEMS Protocol requires BME testing Acceptance Criteria: Not More Than 6.0% Results: B = 2.0% M = 2.1% E = 6.0% All data pass acceptance conclusions. Conclusions? POST PQ MONITORING? 65

66 VALIDATION REPORT Recommended for complex projects Recommended for multiple protocol projects PRIMARY REPORT FOR AUDIT Cut and Paste exercise from multiple documents Best approach to avoid inconsistency 66

67 VALIDATION REPORT FORMAT Introduction Key information from Validation Plan Supporting information Protocol #1 results Cut and paste Protocol #2 results Cut and paste Protocol #3 results Cut and paste Protocol #n results Cut and paste Write transitional narrative Project conclusions (for Validation Plan) Validation statement Results indicate that is validated. HAVE MODEL DOCUMENTS AVAILABLE 67

68 STAGE 3 DOCUMENTS CONTINUED PROCESS VERIFICATION POST PQ DOCUMENTS TYPES OF DOCUMENTS Post PQ requirements work required based on PQ results Example: B = 1.5%, M = 1.8%, E = 6.0% -- all results pass. Ongoing monitoring routine process monitoring 68

69 STAGE 3 DOCUMENT RESONSIBILITIES PQ REQUIREMENTS Requirements specified in PQ results Continued monitoring of critical test results High risk activities Continued monitoring of aberrant values Continued monitoring of statistical (CL) failures 69

70 STAGE 3 DOCUMENT RESPONSIBILITIES ONGOING MONITORING RESPONSIBILITY Monitoring results (Annual Product Review) Change control validation results/reports and monitoring Non-conformances Deviations Process monitoring (control charts) Process changes Improvement projects instituted QA Validation Production Production QA Other changes Record of management review ANNUAL REVIEW NOT GOOD ENOUGH, ESPECIALLY FOR HIGH RISK PROCESSES Production Validation QA 70

71 STAGE 3 DOCUMENTS Regular management review of manufacturing data Data analysis by statistical process control (SPC) principles Review of all associated events, investigations, changes, etc. Record of management review Expanded Annual Product Review, conducted at appropriate intervals based on risk. 71

72 ASSOCIATED VALIDATION AND QUALIFICATION DOCUMENTS Equipment qualification All manufacturing process equipment and associated control systems Example: Drug dispensing qualification (equipment, facilities, HVAC, personnel, etc.) All facilities, utilities, systems, etc. Analytical method validation Analytical equipment qualification ABOVE MENTIONED IN PV GUIDANCE 72

73 IQ, OQ, PQ ASTM E2500 EQUIPMENT, FACILITIES, UTILTIES, ETC. QUALIFICATION Same approach and philosophy as with processes understand, demonstrate, and maintain Confirmation -- Success I expected. Same requirements Same approval Critical tests only Non-critical tests in FAC, SAC, etc. Do as much as possible in commissioning Difference from PV: Do tests only once Validation statement Results indicate that is qualified. 73

74 ANALYTICAL Analytical methods validated Analytical equipment qualified QbD for analytical methods evolving 74

75 OTHER ASSOCIATED DOCUMENTS Training records Operators Approvers Supervisors Personnel qualifications FDA Warning Letter for inconsistent job requirements (HR) and personnel resumes Environmental monitoring history Other 75

76 DOCUMENT OUTLINES vs. TEMPLATES Document templates very difficult Labor intensive Do not fit every situation Suggested approach Document outline of major sections Document outline evolves Model approved documents available Model approved documents improved and are replaced 76

77 VALIDATION DOCUMENT APPROVAL VALIDATION APPROVAL COMMITTEE (VAC) VAC must review documents with perspective of an external regulatory auditor Assure acceptability of technical validation and product quality Assure compliance with regulations, policies, and industry expectations Assure acceptability of documentation. Spelling and grammar VAC IMPORTANT PARTNER WITH VALIDATION 77

78 VALIDATION DOCUMENT APPROVAL Technical validation Scientific and technical principles Consistent approach Supports objective of validation Supports routine manufacturing in type of testing and sampling Support routine manufacturing in duration of sampling and testing Results and discussion support data Correct technical conclusions Equipment testing support entire operating range used in manufacturing 78

79 VALIDATION APPROVAL COMMITTEE Training consistent with area of expertise Specialized training on validation function Emphasize role of internal auditor VALIDATION APPROVAL COMMITTEE IS NOT Training for new personnel Expeditor for engineering documents 79

80 Plan implementation strategy IMPLEMENTATION Assemble PV Guidance and other references Meet with affected groups R&D, Engineering, Technical Support, QA, others Meet with Validation Approval Committee Develop reasonable and deliberate strategy with guaranteed success Upper management input Upper management approval General training on validation all including new groups involved in validation Protocol writer training Expectations for documents Validation Approval Committee responsibilities Science and technical basis Compliance with procedures Documentation quality Surrogate regulatory auditor Validation Approval Committee training 80

81 IMPLEMENTATION -- REALITY Develop reasonable and deliberate strategy Assure successful implementation Do not expect rapid success Do not expect agreements and support Expect complaints and problems OPPORTUNITY FOR VALIDATION LEADERSHIP 81

82 SUMMARY WHERE WE ARE -- CURRENT PRACTICE R&D Validation Commercialization 82

83 SUMMARY -- VALIDATION CURRENT PRACTICE Emphasis on repeatability (3x) One-time effort Documentation important Last step in development Hope we can pass validation Required for product release to market Key regulations: 1987 Process Validation Guidance 1990 s Pharma Inspection Guidelines 1997 Medical Device Quality Systems Manual 83

84 SUMMARY -- WHERE WE ARE GOING LIFECYCLE APPROACH TO PROCESS VALIDATION Lifecycle approach: Validation is never completed Validation is always ongoing Objectives: Scientific and technical process Demonstrate process works as intended Process must remain in control throughout lifecycle EFFECTIVE DOCUMENTS CONSISTENT WITH THE ABOVE 84

85 LIFECYCLE APPROACH TO PROCESS VALIDATION Process Design Studies to establish process Identify critical process parameters Identify sources of variation Consider range of variation possible in processes Process understanding Process Qualification Equipment, facilities, and utilities Confirm commercial process design Validation performance Continued process verification Monitor, collect information, assess Maintenance, continuous verification, process improvement Change control Validation maintenance The process of process validation. 85

86 SUMMARY PROCESS VALIDATION HISTORY 1978 CGMP includes Validation 1987 Development -- VALIDATION -- Control Lifecycle approach Continuum of understanding validation maintenance UNDERSTANDING -- VALIDATION -- MAINTENANCE 86

87 SUMMARY VALIDATION -- FUTURE Development Performance Maintenance Stage 1 Stage 2 Stage 3 87

88 SUMMARY COMPREHENSIVE, CONSISTENT, AND EFFECTIVE VALIDATION DOCUMENTS Validation documents consistent with validation guidelines and expectations based on risk Policies and VMP Stage 1 -- Emphasis on development work supporting Stage 2 Technical basis for validation Stage 2 -- Work should consider validation guidance recommendations Plans, protocols, results Stage 3 Emphasis on maintaining validated state through lifecycle Specific needs and routine monitoring Associated documents 88

89 SUMMARY VALIDATION POLICIES Corporate or company policies High level overview documents State agreement with local regulatory requirements and customer regulatory documents Describe general validation approach State key points from Process Validation Guidance Risk-based approach 89

90 SUMMARY VALIDATION MASTER PLAN Program description at site Multi-chapter document Updated as needed (annual, quarterly, monthly) Improvement projects commitments and timelines Consistent with corporate policies State key points from Process Validation Guidance Risk-based approach 90

91 SUMMARY STAGE 1 DOCUMENTS Technical understanding of processes -- basis of validation Reports readily available Accessed throughout product lifecycle Stand-alone documents Applies to processes, cleaning, analytical, equiment, facilities, utilities, control systems, others. R&D / TECHNICAL AREAS NOT ACCUSTOMED TO THESE REQUIREMENTS 91

92 SUMMARY STAGE 2 DOCUMENTS VALIDATION REQUEST / PLAN Initiates validation Provides basis and details of future work Lists all specific requirements to complete validation Administrative importance Most important document all subsequent documents based on validation plan Risk based 92

93 SUMMARY STAGE 2 DOCUMENTS VALIDATION PROTOCOLS Specific guidance requirements Strategy and approach Impact of change Risk based Testing and sampling rationale Acceptance criteria Statistical data treatment Data sheets Post-validation monitoring plan 93

94 SUMMARY STAGE 2 DOCUMENTS VALIDATION RESULTS / REPORTS Data sheets Discussion of results Evaluate results Additional post-validation testing if necessary Validation statement is validated. Summary report for multiple protocol validation or complex projects Stage 3 Plan included in results document Most important validation document Simple sentences, simple words Written for the reader 94

95 SUMMARY STAGE 3 DOCUMENTS CONTINUED PROCESS VERIFICATION Special post-pq requirements Based on unexpected results Routine monitoring Risk based 95

96 SUMMARY ASSOCIATED DOCUMENTS Equipment, facilities, utilities, etc. qualification Analytical methods and equipment Training records Personnel qualification Environmental monitoring 96

97 SUMMARY OTHER CONSIDERATIONS Follow FDA PV Guidance Use outlines Have model documents available Continually improve model documents Based on guidance requirements Example information to provide expectations for writers and approvers Write most important document sections first Consider problem examples FMEA risk analysis included with validation plan 97

98 SUMMARY -- IMPLEMENTATION Plan implementation strategy Develop reasonable and deliberate strategy Guarantee success Upper management input and approval Validation Approval Committee agreement Validation Approval Committee responsibilities General training on validation including new groups involved in validation Protocol writer training Validation Approval Committee training Expect difficulty 98

99 SUMMARY -- FINAL 1. Comprehensive and consistent approach to documentation High level documents Stage documents Associated documents 2. Lifecycle approach principles Key concepts and details -- Terminology 3. Documents structures Outlines Examples Problems 4. Implementation Paradigm shift Training 99

100 PAUL L. PLUTA, PhD Editor-in-Chief Journal of Validation Technology Journal of GXP Compliance Advanstar Communications Visiting Clinical Associate Professor University of Illinois at Chicago (UIC) College of Pharmacy Chicago, IL, USA Contact: 100

Process Validation: Practical Aspects of the New FDA Guidance

Process Validation: Practical Aspects of the New FDA Guidance Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control

More information

What is Process Validation?

What is Process Validation? What is Process Validation? Process Validation is defined as the collection and evaluation of data, from the process design stage throughout production, which establishes scientific evidence that a process

More information

[ABOUT THE AUTHOR. FDA Lifecycle Approach to Process Validation What, Why, and How? PQ Forum. Paul L. Pluta]

[ABOUT THE AUTHOR. FDA Lifecycle Approach to Process Validation What, Why, and How? PQ Forum. Paul L. Pluta] Paul L. Pluta] FDA Lifecycle Approach to Process Validation What, Why, and How? Paul L. Pluta PQ Forum provides a mechanism for validation practitioners to share information about Stage 2 process qualification

More information

White paper: FDA Guidance for Industry Update Process Validation

White paper: FDA Guidance for Industry Update Process Validation White paper: FDA Guidance for Industry Update Process Validation In January 2011, the FDA released the final version of its long-awaited update to its Process Validation Guidance for Industry. Since then,

More information

Guideline on Process Validation

Guideline on Process Validation 1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/INF 11/2015 1 April 2015 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * * Entry into force:

More information

FDA Guidance for Industry Update - Process Validation

FDA Guidance for Industry Update - Process Validation FDA Guidance Update: Process Validation: General Principles and Practices White Paper FDA Guidance for Industry Update - Process Validation The changing face of Validation; are IQ, OQ and PQ really dead

More information

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management

More information

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

Implementing New USP Chapters for Analytical Method Validation

Implementing New USP Chapters for Analytical Method Validation Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments

More information

Workshop A Design Space (DS)

Workshop A Design Space (DS) Implementation of ICH Q8, Q9, Q10 Workshop A Design Space (DS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Disclaimer The information

More information

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical

More information

Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs)

Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs) Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs) Cornelia Kamp, MBA Executive Director Strategic Initiatives Tim Hackett Director

More information

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)

More information

Like-For-Like Changes: Is Validation Testing Needed? Validation Case Study #7

Like-For-Like Changes: Is Validation Testing Needed? Validation Case Study #7 Paul L. Pluta] Like-For-Like Changes: Is Validation Testing Needed? Validation Case Study #7 Paul L. Pluta Validation Case Studies discusses validation situations useful to practitioners in validation

More information

Guidance on Qualification of existing facilities, systems, equipment and utilities

Guidance on Qualification of existing facilities, systems, equipment and utilities QUALIFICATION_EXISTING_EQUIPMENT_FINAL page 1 / 16 1. Acknowledgement...3 2. Introduction...3 3. Scope...4 4. Regulatory requirements...4 5. Guidance...4 5.1 Risk Assessment... 4 5.2 Procedure... 7 5.3

More information

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December

More information

Quality by Design (QbD) Overview

Quality by Design (QbD) Overview Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System

More information

Overview of Pre-Approval Inspections

Overview of Pre-Approval Inspections Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval

More information

State of Control Over the Lifecycle and Process Validation (New and Legacy Products)

State of Control Over the Lifecycle and Process Validation (New and Legacy Products) State of Control Over the Lifecycle and Process Validation (New and Legacy Products) Grace McNally Branch Chief (acting), Regulatory Policy and Collaboration Branch FDA/CDER/Office of Compliance ICH Q10,

More information

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration & Preventative Maintenance Sally Wolfgang Manager, Quality Operations Merck & Co., Inc. Calibration: A comparison of two instruments or measuring devices one of which is a standard of known

More information

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing

More information

Library Guide: Pharmaceutical GMPs

Library Guide: Pharmaceutical GMPs Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA

More information

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where

More information

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015

MHRA GMP Data Integrity Definitions and Guidance for Industry January 2015 MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This

More information

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality

More information

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

1.0 INTRODUCTION 1.1 Overview

1.0 INTRODUCTION 1.1 Overview Guidance document for the writing of standard operating procedures (Taken from United States Environmental Protection Agency Guidance for Preparing Standard Operating Procedures (SOPs) EPA QA/G- 6 [EPA/600/B-

More information

Installation and Operational Qualification Protocol (Reference: SOP )

Installation and Operational Qualification Protocol (Reference: SOP ) Project Name Equipment Process Line/Location Project Number Serial Number Model Number Protocol number WRITTEN BY: REVIEWED BY: Position APPROVAL TO EXECUTE: Position: PROTOCOL COMPLETION APPROVAL: Position:

More information

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015

MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015 MHRA GMP Data Integrity Definitions and Guidance for Industry Introduction: Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality. This

More information

Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics

Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics Pharmaceutical Product Quality, Quality by Design, cgmp, and Quality Metrics Lawrence X. Yu, Ph.D. Deputy Director Office of Pharmaceutical Quality Center for Drug Evaluation and Research Food and Drug

More information

QUALITY MANUAL REVISION RECORD

QUALITY MANUAL REVISION RECORD Page 2 of 31 REVISION RECORD Date Rev Description Jun 18, 2007 N/C Original Issue Sep 16, 2009 A Update to ISO 9001:2008 Standard. Feb 04, 2010 B Revised exclusions, removed (Except 7.3.7 from the exclusion

More information

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address: NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to

INTRODUCTION. This book offers a systematic, ten-step approach, from the decision to validate to INTRODUCTION This book offers a systematic, ten-step approach, from the decision to validate to the assessment of the validation outcome, for validating configurable off-the-shelf (COTS) computer software

More information

ICH Q10 - Pharmaceutical Quality System

ICH Q10 - Pharmaceutical Quality System WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,

More information

TrackWise - Quality Management System

TrackWise - Quality Management System TrackWise - Quality Management System Focus area: Electronic Management of CAPA Systems in the Regulated Industry May 11, 2007 Yaniv Vardi VP, Operations Sparta Systems Europe, Ltd. Agenda Sparta Systems

More information

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

AS9100 Quality Manual

AS9100 Quality Manual Origination Date: August 14, 2009 Document Identifier: Quality Manual Revision Date: 8/5/2015 Revision Level: Q AS 9100 UNCONTROLLED IF PRINTED Page 1 of 17 1 Scope Advanced Companies (Advanced) has established

More information

Annex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70

Annex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70 Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating

More information

QbD Considerations for Analytical Methods - FDA Perspective

QbD Considerations for Analytical Methods - FDA Perspective QbD Considerations for Analytical Methods - FDA Perspective IFPAC Annual Meeting Baltimore, January 25, 2013 Sharmista Chatterjee, Ph.D. CMC Lead for QbD ONDQA/CDER/FDA Outline Role of analytics in drug

More information

Process Validation for Medical Devices

Process Validation for Medical Devices Process Validation for Medical Devices Dan O Leary CBA, CQE, CRE, CSSBB, CIRM, LLC 603-209-0600 OmbuEnterprises@msn.com Copyright 2010 by, LLC Process Validation for Medical Devices 1 Instructor Introduction

More information

AN OVERVIEW OF PHARMACEUTICAL VALIDATION: QUALITY ASSURANCE VIEW POINT

AN OVERVIEW OF PHARMACEUTICAL VALIDATION: QUALITY ASSURANCE VIEW POINT INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Review Article AN OVERVIEW OF PHARMACEUTICAL VALIDATION: QUALITY ASSURANCE VIEW POINT L. Nandhakumar*, G. Dharmamoorthy,

More information

Medical Device Training Program 2015

Medical Device Training Program 2015 Medical Device Training Introduction Supplementary training and education is often overlooked by medical device professionals until it is triggered by an upcoming FDA or Notified Body and/or ISO 13485

More information

GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme

GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES. Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme GOOD DOCUMENTATION AND QUALITY MANAGEMENT PRINCIPLES Vimal Sachdeva Technical Officer (Inspector), WHO Prequalification of Medicines Programme Contents 1. Why good documentation is essential? 2. What constitutes

More information

OPERATIONAL STANDARD

OPERATIONAL STANDARD 1 of 11 1. Introduction The International Safe Transit Association (ISTA), a non-profit association whose objective is to prevent product damage and excess packaging usage within the distribution environment.

More information

Computer System Validation - It s More Than Just Testing

Computer System Validation - It s More Than Just Testing Computer System Validation - It s More Than Just Testing Introduction Computer System Validation is the technical discipline that Life Science companies use to ensure that each Information Technology application

More information

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,

More information

Risk Based Pre-Approval Inspection

Risk Based Pre-Approval Inspection Risk Based Pre-Approval Inspection PQRI-FDA Conference on Advancing Product Quality October 5, 2015 Christine Moore, Ph.D. Acting Director, Office of Process and Facilities FDA/CDER/OPQ Outline Background

More information

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations

More information

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations

Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations Implementing Lifecycle Validation Practices at Contract Manufacturing Organizations This paper discusses the nuances of lifecycle validation implementation at contract manufacturing organizations (CMOs).

More information

ISSN 2347-9531 (Print)

ISSN 2347-9531 (Print) Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2014; 3(2): 178-190 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com

More information

Transfer of a manufacturing process: Case study ~ Solid dosage transfer within technical operations Ian Flawn Orpana QPharma AB, Sweden

Transfer of a manufacturing process: Case study ~ Solid dosage transfer within technical operations Ian Flawn Orpana QPharma AB, Sweden Transfer of a manufacturing process: Case study ~ Solid dosage transfer within technical operations Ian Flawn rpana QPharma AB, Sweden verview of Product Product fitted into therapeutic area Purchased

More information

Supplier Quality Management System Audit Checklist (ISO 9000:2000, TS 16949:2002)

Supplier Quality Management System Audit Checklist (ISO 9000:2000, TS 16949:2002) Supplier Quality Management System Audit Checklist (ISO 9000:2000, TS 16949:2002) Supplier: Plant/Location: Date: Audit Team: Scope of Audit: Number of C.A.R. s: Corrective Action Due: Potential suppliers

More information

GAMP5 - a lifecycle management framework for customized bioprocess solutions

GAMP5 - a lifecycle management framework for customized bioprocess solutions GE Healthcare Life Sciences GAMP5 - a lifecycle management framework for customized bioprocess solutions imagination at work GE Healthcare s engineering department, Customized Bioprocess Solutions (CBS),

More information

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,

More information

Compliance Case Study #3 Manual Processes, Performance, Responsibilities, and Training

Compliance Case Study #3 Manual Processes, Performance, Responsibilities, and Training Compliance Case Study #3 Manual Processes, Performance, Responsibilities, and Training Paul L. Pluta, Timothy J. Fields, and Alan J. Smith IMAGEZOO/GETTY IMAGES Compliance Case Studies discusses compliance

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE

More information

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations Application of Quality Risk Management to Pharmaceutical Operations Eldon Henson, Vice President, Quality Operations Key Topics of Discussion Definition of Quality Risk Management (QRM) Overview of PDA

More information

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session 6: WHO Prequalification Programme Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs Session adapted from the WHO training workshop on prequalification and the WHO technical briefing seminar

More information

QbD Approach to Assay Development and Method Validation

QbD Approach to Assay Development and Method Validation QbD Approach to Assay Development and Method Validation Thomas A. Little Ph.D. 11/105/2014 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com

More information

Validation and Calibration. Definitions and Terminology

Validation and Calibration. Definitions and Terminology Validation and Calibration Definitions and Terminology ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with an

More information

Computerised Systems. Seeing the Wood from the Trees

Computerised Systems. Seeing the Wood from the Trees Computerised Systems Seeing the Wood from the Trees Scope WHAT IS A COMPUTERISED SYSTEM? WHY DO WE NEED VALIDATED SYSTEMS? WHAT NEEDS VALIDATING? HOW DO WE PERFORM CSV? WHO DOES WHAT? IT S VALIDATED -

More information

Quality Risk Management ICH Q9 & ISO 14971. Presented by Michael Kerr 11 th November 2011

Quality Risk Management ICH Q9 & ISO 14971. Presented by Michael Kerr 11 th November 2011 Quality Risk Management ICH Q9 & ISO 14971 Presented by Michael Kerr 11 th November 2011 Agenda Risk Concept QRM Fundamentals Regulatory Expectations Warning Letters / Observations Application of QRM Introduction:

More information

Assay Development and Method Validation Essentials

Assay Development and Method Validation Essentials Assay Development and Method Validation Essentials Thomas A. Little Ph.D. 10/13/2012 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland, UT 84003 1-925-285-1847 drlittle@dr-tom.com

More information

PROPOSED DOCUMENT. Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change

PROPOSED DOCUMENT. Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change AHWP/WG3/P001:2013 PROPOSED DOCUMENT Title: Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change Author: AHWP Work Group 3 Date: 13 November

More information

MeriCal Quality Profile

MeriCal Quality Profile January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.

More information

Corrective and Preventive Actions

Corrective and Preventive Actions Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What

More information

OVERVIEW OF STANDARD 7E & STANDARD 20

OVERVIEW OF STANDARD 7E & STANDARD 20 Standard for Thermal Transport Packaging Used in Parcel Delivery System Shipment 7E 2 010 ISTA 7E Usage Modes VERSION DATE OCTOBER 2010 Initial Release ISTA, Distributing Confidence, Worldwide ISTA 7-Series

More information

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Presenter Marsha Stabler Hardiman Over 20 years experience in the

More information

Testing Automated Manufacturing Processes

Testing Automated Manufacturing Processes Testing Automated Manufacturing Processes (PLC based architecture) 1 ❶ Introduction. ❷ Regulations. ❸ CSV Automated Manufacturing Systems. ❹ PLCs Validation Methodology / Approach. ❺ Testing. ❻ Controls

More information

Software Validation in Clinical Trial Reporting: Experiences from the Biostatistical & Data Sciences Department

Software Validation in Clinical Trial Reporting: Experiences from the Biostatistical & Data Sciences Department Software Validation in Clinical Trial Reporting: Experiences from the Biostatistical & Data Sciences Department Andrea Baker Senior Programmer GlaxoSmithKline SeUGI 19 Florence May 29-June 1 2001 Introduction

More information

Revision Date Author Description of change. 10 07Jun13 Mark Benton Removed Admin. Manager from approval

Revision Date Author Description of change. 10 07Jun13 Mark Benton Removed Admin. Manager from approval Page 2 of 15 Document Revision History Revision Date Author Description of change 10 07Jun13 Mark Benton Removed Admin. Manager from approval 12Feb13 Mark Benton 08 01Oct12 Mark Benton 07 8/30/2012 Refer

More information

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014 Welcome Computer System Validation Training Delivered to FDA ISPE Boston Area Chapter February 20, 2014 1 Background Training Conducted on April 24, 2012 Food & Drug Administration Division of Manufacturing

More information

PHARMACEUTICAL OUTSOURCING:

PHARMACEUTICAL OUTSOURCING: PHARMACEUTICAL OUTSOURCING: QUALITY MANAGEMENT AND PROJECT DELIVERY Trevor Deeks, Karen Ginsbury and Susan Schniepp Editors CONTENTS Preface 1 OVERVIEW OF OUTSOURCED OPERATIONS Susan Schniepp 2 LEGAL ASPECTS

More information

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:

More information

Deviation and Out of Specification Handling

Deviation and Out of Specification Handling Deviation and Out of Specification Handling APV Training Course GMP Requirements June,10th to11th 2004 Istanbul, Turkey Dr. Jürgen Mählitz GMP Inspector Fronhof 10 D-86152 Augsburg Germany Dr. Jürgen Mählitz

More information

White paper: How to implement a Quality Management System

White paper: How to implement a Quality Management System White paper: How to implement a Quality Management System This whitepaper will help you to implement a Quality Management System (QMS), based on Good Manufacturing Practice (GMP), ISO 9001 or ISO 13485

More information

Monitoring the autoclaving process in the pharmaceutical industry

Monitoring the autoclaving process in the pharmaceutical industry Application Description AD/RandC/006-EN Monitoring the autoclaving process in the pharmaceutical industry - Provides independent verification and validation monitoring of the autoclaving process - Enables

More information

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting

More information

Best Practice In A Change Management System

Best Practice In A Change Management System Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits

More information

QUALITY RISK MANAGEMENT (QRM): A REVIEW

QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 149-154 149 Available online at http://jddtonline.info REVIEW ARTICLE QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar MV Head Corporate

More information

Clinical database/ecrf validation: effective processes and procedures

Clinical database/ecrf validation: effective processes and procedures TITOLO SLIDE Testo Slide Testo Slide Testo Slide Clinical database/ecrf validation: effective processes and procedures IV BIAS ANNUAL CONGRESS Padova September, 26 th 2012 PQE WORKSHOP: What's new in Computerized

More information

ISO 9001:2000 AUDIT CHECKLIST

ISO 9001:2000 AUDIT CHECKLIST ISO 9001:2000 AUDIT CHECKLIST No. Question Proc. Ref. Comments 4 Quality Management System 4.1 General Requirements 1 Has the organization established, documented, implemented and maintained a quality

More information

TG 47-01. TRANSITIONAL GUIDELINES FOR ISO/IEC 17021-1:2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES

TG 47-01. TRANSITIONAL GUIDELINES FOR ISO/IEC 17021-1:2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES TRANSITIONAL GUIDELINES FOR ISO/IEC 17021-1:2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES Approved By: Senior Manager: Mpho Phaloane Created By: Field Manager: John Ndalamo Date of Approval:

More information

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,

More information